ArticleJournal of personalized medicine2021

Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.

Paul Gressenberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.